Minerva Neurosciences CEO to Present at Stifel 2026 Virtual CNS Forum
Event summary
- Minerva Neurosciences CEO Remy Luthringer to present at Stifel 2026 Virtual CNS Forum on March 18, 2026.
- Company initiating confirmatory Phase 3 trial for roluperidone in negative symptoms of schizophrenia.
- Webcast available for 90 days post-event on Minerva's Investors & Media page.
- Investor inquiries directed to CFO Frederick Ahlholm and LifeSci Advisors' Corey Davis.
The big picture
Minerva Neurosciences' participation in the Stifel 2026 Virtual CNS Forum comes at a critical juncture as the company advances its lead candidate, roluperidone, through Phase 3 trials. The presentation provides an opportunity to showcase clinical progress to investors and analysts amid a competitive landscape in CNS disorder treatments. The focus on negative symptoms of schizophrenia highlights Minerva's niche strategy in addressing unmet medical needs.
What we're watching
- Trial Progress
- How the confirmatory Phase 3 trial for roluperidone will impact Minerva's strategic positioning in the CNS disorder market.
- Investor Sentiment
- Whether the presentation will shift investor perception of Minerva's pipeline and execution capabilities.
- Competitive Dynamics
- The pace at which Minerva can differentiate itself from competitors in the schizophrenia treatment space.